Immunoprophylaxis of superficial tumors of the bladder with interferon alfa-2b. our experience
Moyano Calvo, J.L.; Teba del Pino, F.; Sanz Sacristán, J.; Fernández Arjona, M.; Arellano Gañan, R.; Rabadán Ruiz, M.; Herrero Torres, L.; Melón Rey, F.J.; Pereira Sanz, I.
Archivos Espanoles de Urologia 48(1): 55-59
1995
ISSN/ISBN: 0004-0614 PMID: 7733688 Document Number: 447474
The present study was conducted to determine the usefulness of prophylactic therapy with alpha 2b interferon for superficial bladder tumors. Following complete TUR, alpha 2b infereron was administered to 36 patients at a dose of 50 million IU weekly for 3 months and monthly for 9 months. Patients were evaluated every 3 months on the basis of their clinical and analytical data and the cystoscopic findings. Twenty-six patients completed treatment and were evaluable. The follow up and disease-free period was 25.70 months. Recurrence was observed in 38.4% of the patients and tumor progression in 3.8%. Alpha 2b interferon is useful in the prevention of tumor recurrence. Its utility is similar to that of other drugs currently used.